[
    {
        "text": "based on the currently available data",
        "start": 0.399,
        "duration": 3.601
    },
    {
        "text": "the commissioner who medicine is",
        "start": 2.639,
        "duration": 3.361
    },
    {
        "text": "advising the following",
        "start": 4.0,
        "duration": 4.639
    },
    {
        "text": "first our pregnant women should continue",
        "start": 6.0,
        "duration": 3.92
    },
    {
        "text": "to discuss with the healthcare",
        "start": 8.639,
        "duration": 2.161
    },
    {
        "text": "professional",
        "start": 9.92,
        "duration": 2.799
    },
    {
        "text": "whether the benefits of having the",
        "start": 10.8,
        "duration": 3.44
    },
    {
        "text": "vaccine outweigh",
        "start": 12.719,
        "duration": 4.721
    },
    {
        "text": "the risks for them number two",
        "start": 14.24,
        "duration": 5.039
    },
    {
        "text": "people with a history of blood disorders",
        "start": 17.44,
        "duration": 3.599
    },
    {
        "text": "that increase the risk of clotting",
        "start": 19.279,
        "duration": 3.361
    },
    {
        "text": "should only have the covet 19",
        "start": 21.039,
        "duration": 3.041
    },
    {
        "text": "vaccinations",
        "start": 22.64,
        "duration": 3.84
    },
    {
        "text": "when the benefits outweigh any potential",
        "start": 24.08,
        "duration": 4.0
    },
    {
        "text": "risks",
        "start": 26.48,
        "duration": 3.92
    },
    {
        "text": "number three anyone who experienced",
        "start": 28.08,
        "duration": 3.039
    },
    {
        "text": "cerebral",
        "start": 30.4,
        "duration": 2.8
    },
    {
        "text": "or other major blood clots occurring",
        "start": 31.119,
        "duration": 4.481
    },
    {
        "text": "together with low levels of platelets",
        "start": 33.2,
        "duration": 5.679
    },
    {
        "text": "after the first vaccine of courage 19",
        "start": 35.6,
        "duration": 7.24
    },
    {
        "text": "astrazeneca should not have the second",
        "start": 38.879,
        "duration": 5.2
    },
    {
        "text": "dose",
        "start": 42.84,
        "duration": 3.719
    },
    {
        "text": "we will be continually monitoring uh",
        "start": 44.079,
        "duration": 4.32
    },
    {
        "text": "further reports as they come in",
        "start": 46.559,
        "duration": 4.64
    },
    {
        "text": "uh continuing monitoring other aspects",
        "start": 48.399,
        "duration": 3.68
    },
    {
        "text": "to identify",
        "start": 51.199,
        "duration": 4.0
    },
    {
        "text": "risk factors um so that we can refine",
        "start": 52.079,
        "duration": 6.721
    },
    {
        "text": "the advice that we give at present",
        "start": 55.199,
        "duration": 5.84
    },
    {
        "text": "the data on people who've had two doses",
        "start": 58.8,
        "duration": 4.8
    },
    {
        "text": "of the covered 19 astrozenica vaccine",
        "start": 61.039,
        "duration": 3.361
    },
    {
        "text": "are limited",
        "start": 63.6,
        "duration": 2.72
    },
    {
        "text": "because these events are rare and",
        "start": 64.4,
        "duration": 3.759
    },
    {
        "text": "comparatively small number",
        "start": 66.32,
        "duration": 3.839
    },
    {
        "text": "of second doses have been given",
        "start": 68.159,
        "duration": 4.32
    },
    {
        "text": "therefore it is not possible to draw a",
        "start": 70.159,
        "duration": 3.201
    },
    {
        "text": "conclusion",
        "start": 72.479,
        "duration": 2.881
    },
    {
        "text": "about how frequently blood clots with a",
        "start": 73.36,
        "duration": 3.28
    },
    {
        "text": "low platelet count",
        "start": 75.36,
        "duration": 3.2
    },
    {
        "text": "happen following a second dose of the",
        "start": 76.64,
        "duration": 3.92
    },
    {
        "text": "vaccine but this will be monitored",
        "start": 78.56,
        "duration": 3.68
    },
    {
        "text": "closely by the mhra",
        "start": 80.56,
        "duration": 5.04
    },
    {
        "text": "and by the chm as part of the ongoing",
        "start": 82.24,
        "duration": 4.72
    },
    {
        "text": "review",
        "start": 85.6,
        "duration": 4.24
    },
    {
        "text": "so just to put into context these events",
        "start": 86.96,
        "duration": 4.24
    },
    {
        "text": "are extremely rare",
        "start": 89.84,
        "duration": 3.36
    },
    {
        "text": "as june has already mentioned and i want",
        "start": 91.2,
        "duration": 3.2
    },
    {
        "text": "to put into context",
        "start": 93.2,
        "duration": 3.919
    },
    {
        "text": "in relation to covet 19 itself it is",
        "start": 94.4,
        "duration": 4.48
    },
    {
        "text": "important to remember the covet 19",
        "start": 97.119,
        "duration": 2.64
    },
    {
        "text": "itself",
        "start": 98.88,
        "duration": 4.16
    },
    {
        "text": "causes clotting and it causes lowered",
        "start": 99.759,
        "duration": 4.881
    },
    {
        "text": "platelets and i've got a few figures",
        "start": 103.04,
        "duration": 3.359
    },
    {
        "text": "from a paper which is recently",
        "start": 104.64,
        "duration": 4.96
    },
    {
        "text": "published pulmonary embolus clots on the",
        "start": 106.399,
        "duration": 3.68
    },
    {
        "text": "lungs",
        "start": 109.6,
        "duration": 2.72
    },
    {
        "text": "occurring 7.8 percent of people who have",
        "start": 110.079,
        "duration": 3.68
    },
    {
        "text": "curved 19",
        "start": 112.32,
        "duration": 3.92
    },
    {
        "text": "dvt deep venous thrombosis clots in the",
        "start": 113.759,
        "duration": 5.121
    },
    {
        "text": "legs occurring 11.2 percent",
        "start": 116.24,
        "duration": 6.159
    },
    {
        "text": "uh who've had uh covert 19. and",
        "start": 118.88,
        "duration": 5.519
    },
    {
        "text": "um of those people who've been infected",
        "start": 122.399,
        "duration": 3.281
    },
    {
        "text": "with sars curvy 2",
        "start": 124.399,
        "duration": 4.48
    },
    {
        "text": "getting curved 19 and ending up in itu",
        "start": 125.68,
        "duration": 7.68
    },
    {
        "text": "23 will have some form of clot",
        "start": 128.879,
        "duration": 4.481
    },
    {
        "text": "covered 19 also causes strokes in about",
        "start": 133.68,
        "duration": 4.8
    },
    {
        "text": "1.6 percent",
        "start": 136.16,
        "duration": 4.64
    },
    {
        "text": "and up to 30 percent of people who",
        "start": 138.48,
        "duration": 3.68
    },
    {
        "text": "develop covert 19",
        "start": 140.8,
        "duration": 3.36
    },
    {
        "text": "i will get thrombocytopenia which is",
        "start": 142.16,
        "duration": 4.079
    },
    {
        "text": "lowering of the platelet count",
        "start": 144.16,
        "duration": 4.88
    },
    {
        "text": "and that puts into context that the risk",
        "start": 146.239,
        "duration": 3.841
    },
    {
        "text": "of clots",
        "start": 149.04,
        "duration": 2.88
    },
    {
        "text": "and lowered platelet is much higher with",
        "start": 150.08,
        "duration": 4.0
    },
    {
        "text": "covered 19 than these extremely rare",
        "start": 151.92,
        "duration": 3.76
    },
    {
        "text": "events which are occurring",
        "start": 154.08,
        "duration": 5.2
    },
    {
        "text": "with a vaccine so to finish off the chm",
        "start": 155.68,
        "duration": 5.279
    },
    {
        "text": "has advised that the link between the",
        "start": 159.28,
        "duration": 3.599
    },
    {
        "text": "vaccine and blood clots",
        "start": 160.959,
        "duration": 4.161
    },
    {
        "text": "in the cerebral and other veins",
        "start": 162.879,
        "duration": 3.521
    },
    {
        "text": "occurring together with lowered",
        "start": 165.12,
        "duration": 2.0
    },
    {
        "text": "platelets",
        "start": 166.4,
        "duration": 3.6
    },
    {
        "text": "is getting firmer but absolute proof of",
        "start": 167.12,
        "duration": 4.56
    },
    {
        "text": "the link between the vaccine and adverse",
        "start": 170.0,
        "duration": 2.239
    },
    {
        "text": "events",
        "start": 171.68,
        "duration": 3.919
    },
    {
        "text": "will need extensive scientific work",
        "start": 172.239,
        "duration": 4.64
    },
    {
        "text": "based on the currently available",
        "start": 175.599,
        "duration": 4.321
    },
    {
        "text": "evidence and the benefit risks remains",
        "start": 176.879,
        "duration": 4.961
    },
    {
        "text": "favorable for the vast majority people",
        "start": 179.92,
        "duration": 3.2
    },
    {
        "text": "but as june said",
        "start": 181.84,
        "duration": 3.44
    },
    {
        "text": "is more finely balanced for the younger",
        "start": 183.12,
        "duration": 3.52
    },
    {
        "text": "people and",
        "start": 185.28,
        "duration": 3.12
    },
    {
        "text": "we are advising that this evolving",
        "start": 186.64,
        "duration": 3.76
    },
    {
        "text": "evidence should be taken into account",
        "start": 188.4,
        "duration": 4.64
    },
    {
        "text": "when considering the use of the vaccine",
        "start": 190.4,
        "duration": 6.24
    },
    {
        "text": "i'll hand back to professor van tan",
        "start": 193.04,
        "duration": 6.16
    },
    {
        "text": "thank you professor serbaneer thank you",
        "start": 196.64,
        "duration": 3.92
    },
    {
        "text": "professor brain",
        "start": 199.2,
        "duration": 4.72
    },
    {
        "text": "you've now heard from the regulatory",
        "start": 200.56,
        "duration": 4.399
    },
    {
        "text": "experts",
        "start": 203.92,
        "duration": 4.08
    },
    {
        "text": "and in a moment i will turn to the new",
        "start": 204.959,
        "duration": 4.161
    },
    {
        "text": "advice from",
        "start": 208.0,
        "duration": 4.799
    },
    {
        "text": "the jcvi with professor lim but before",
        "start": 209.12,
        "duration": 6.56
    },
    {
        "text": "we do that i'd like to put into context",
        "start": 212.799,
        "duration": 3.36
    },
    {
        "text": "in a",
        "start": 215.68,
        "duration": 4.4
    },
    {
        "text": "visual way what the data are telling us",
        "start": 216.159,
        "duration": 6.8
    },
    {
        "text": "in terms of uh benefits and risks so if",
        "start": 220.08,
        "duration": 3.36
    },
    {
        "text": "i could",
        "start": 222.959,
        "duration": 4.0
    },
    {
        "text": "have the first slide please",
        "start": 223.44,
        "duration": 6.079
    },
    {
        "text": "so this slide and i'll go through the",
        "start": 226.959,
        "duration": 3.601
    },
    {
        "text": "first one",
        "start": 229.519,
        "duration": 4.881
    },
    {
        "text": "slowly shows you in blue type to the",
        "start": 230.56,
        "duration": 5.36
    },
    {
        "text": "left of the slide",
        "start": 234.4,
        "duration": 5.44
    },
    {
        "text": "the potential benefits from",
        "start": 235.92,
        "duration": 7.36
    },
    {
        "text": "vaccination and on the orange part to",
        "start": 239.84,
        "duration": 4.319
    },
    {
        "text": "the right",
        "start": 243.28,
        "duration": 4.319
    },
    {
        "text": "the potential harms and you can see that",
        "start": 244.159,
        "duration": 5.681
    },
    {
        "text": "as you go down the slide from top to",
        "start": 247.599,
        "duration": 3.36
    },
    {
        "text": "bottom",
        "start": 249.84,
        "duration": 4.24
    },
    {
        "text": "those benefits and potential",
        "start": 250.959,
        "duration": 7.041
    },
    {
        "text": "harms are arrayed by age band",
        "start": 254.08,
        "duration": 7.04
    },
    {
        "text": "starting at 20 to 29 young adults",
        "start": 258.0,
        "duration": 6.24
    },
    {
        "text": "through to 60 to 69 relatively",
        "start": 261.12,
        "duration": 6.24
    },
    {
        "text": "old adults and the way",
        "start": 264.24,
        "duration": 6.48
    },
    {
        "text": "these data have been arrayed",
        "start": 267.36,
        "duration": 6.8
    },
    {
        "text": "are in terms of intensive care",
        "start": 270.72,
        "duration": 4.64
    },
    {
        "text": "admissions",
        "start": 274.16,
        "duration": 5.28
    },
    {
        "text": "prevented via vaccine on the left",
        "start": 275.36,
        "duration": 7.44
    },
    {
        "text": "and serious harms potentially due to the",
        "start": 279.44,
        "duration": 4.479
    },
    {
        "text": "vaccine",
        "start": 282.8,
        "duration": 4.0
    },
    {
        "text": "on the right and i thank colleagues at",
        "start": 283.919,
        "duration": 3.921
    },
    {
        "text": "the",
        "start": 286.8,
        "duration": 3.92
    },
    {
        "text": "winton center for um risk risk and",
        "start": 287.84,
        "duration": 4.56
    },
    {
        "text": "evidence communication",
        "start": 290.72,
        "duration": 3.84
    },
    {
        "text": "at cambridge university for help with",
        "start": 292.4,
        "duration": 4.4
    },
    {
        "text": "getting this slide together",
        "start": 294.56,
        "duration": 5.28
    },
    {
        "text": "and this first slide is set as you can",
        "start": 296.8,
        "duration": 4.64
    },
    {
        "text": "see from the title",
        "start": 299.84,
        "duration": 4.96
    },
    {
        "text": "in a scenario of low",
        "start": 301.44,
        "duration": 6.479
    },
    {
        "text": "exposure and in actual fact the rates of",
        "start": 304.8,
        "duration": 5.679
    },
    {
        "text": "disease assumed in this scenario",
        "start": 307.919,
        "duration": 5.441
    },
    {
        "text": "are lower than those we currently have",
        "start": 310.479,
        "duration": 4.16
    },
    {
        "text": "in the uk",
        "start": 313.36,
        "duration": 4.399
    },
    {
        "text": "at the moment and you can see",
        "start": 314.639,
        "duration": 6.4
    },
    {
        "text": "that if you look at the 20 to 29 age",
        "start": 317.759,
        "duration": 4.241
    },
    {
        "text": "band",
        "start": 321.039,
        "duration": 4.0
    },
    {
        "text": "then the potential benefits um",
        "start": 322.0,
        "duration": 6.08
    },
    {
        "text": "amount to 0.8",
        "start": 325.039,
        "duration": 6.321
    },
    {
        "text": "icu admissions averted compared with",
        "start": 328.08,
        "duration": 4.72
    },
    {
        "text": "serious harms",
        "start": 331.36,
        "duration": 5.2
    },
    {
        "text": "of potentially 1.1 but as you",
        "start": 332.8,
        "duration": 7.679
    },
    {
        "text": "go up through the age groups the",
        "start": 336.56,
        "duration": 7.84
    },
    {
        "text": "amount of serious harm declines",
        "start": 340.479,
        "duration": 6.401
    },
    {
        "text": "but the amount of benefit in terms of",
        "start": 344.4,
        "duration": 3.519
    },
    {
        "text": "averted",
        "start": 346.88,
        "duration": 4.56
    },
    {
        "text": "icu admissions becomes much more",
        "start": 347.919,
        "duration": 4.72
    },
    {
        "text": "pronounced",
        "start": 351.44,
        "duration": 3.68
    },
    {
        "text": "and these are arrayed over a 16 week",
        "start": 352.639,
        "duration": 3.28
    },
    {
        "text": "period",
        "start": 355.12,
        "duration": 5.199
    },
    {
        "text": "now we don't expect vaccine to last",
        "start": 355.919,
        "duration": 7.601
    },
    {
        "text": "for 16 weeks we very",
        "start": 360.319,
        "duration": 5.681
    },
    {
        "text": "confidently expect that it is going to",
        "start": 363.52,
        "duration": 5.119
    },
    {
        "text": "be many many months of protection",
        "start": 366.0,
        "duration": 5.199
    },
    {
        "text": "from a vaccine and the reason for using",
        "start": 368.639,
        "duration": 3.68
    },
    {
        "text": "16 weeks",
        "start": 371.199,
        "duration": 4.641
    },
    {
        "text": "is is because that is a typical pandemic",
        "start": 372.319,
        "duration": 4.081
    },
    {
        "text": "wave",
        "start": 375.84,
        "duration": 3.04
    },
    {
        "text": "that's the duration of it but you can",
        "start": 376.4,
        "duration": 3.12
    },
    {
        "text": "see",
        "start": 378.88,
        "duration": 4.96
    },
    {
        "text": "that um at a very low exposure risk",
        "start": 379.52,
        "duration": 5.92
    },
    {
        "text": "lower than we have in the uk at the",
        "start": 383.84,
        "duration": 4.4
    },
    {
        "text": "moment the",
        "start": 385.44,
        "duration": 5.28
    },
    {
        "text": "risk benefit is relatively finely",
        "start": 388.24,
        "duration": 3.76
    },
    {
        "text": "balanced in those",
        "start": 390.72,
        "duration": 3.68
    },
    {
        "text": "younger age groups but it becomes very",
        "start": 392.0,
        "duration": 3.52
    },
    {
        "text": "overwhelming",
        "start": 394.4,
        "duration": 3.519
    },
    {
        "text": "uh in favor of vaccine as you go down",
        "start": 395.52,
        "duration": 4.16
    },
    {
        "text": "the up the ages",
        "start": 397.919,
        "duration": 4.881
    },
    {
        "text": "if we go on to the next slide please",
        "start": 399.68,
        "duration": 6.799
    },
    {
        "text": "this is now a medium risk scenario",
        "start": 402.8,
        "duration": 6.72
    },
    {
        "text": "and it is um set at",
        "start": 406.479,
        "duration": 6.56
    },
    {
        "text": "60 cases per 100 000.",
        "start": 409.52,
        "duration": 7.44
    },
    {
        "text": "that is marginally l higher than the uk",
        "start": 413.039,
        "duration": 5.761
    },
    {
        "text": "average at the moment",
        "start": 416.96,
        "duration": 4.799
    },
    {
        "text": "but it is lower than some of the",
        "start": 418.8,
        "duration": 3.6
    },
    {
        "text": "remaining",
        "start": 421.759,
        "duration": 4.321
    },
    {
        "text": "hot spots in the uk and you can see that",
        "start": 422.4,
        "duration": 6.079
    },
    {
        "text": "when you when the disease is around us",
        "start": 426.08,
        "duration": 2.959
    },
    {
        "text": "more",
        "start": 428.479,
        "duration": 3.44
    },
    {
        "text": "when there's more exposure then the",
        "start": 429.039,
        "duration": 5.201
    },
    {
        "text": "benefits the potential benefits",
        "start": 431.919,
        "duration": 5.28
    },
    {
        "text": "start to stack up but the potential",
        "start": 434.24,
        "duration": 4.799
    },
    {
        "text": "serious harms",
        "start": 437.199,
        "duration": 4.241
    },
    {
        "text": "remain static of course and this is",
        "start": 439.039,
        "duration": 4.0
    },
    {
        "text": "still over a 16",
        "start": 441.44,
        "duration": 3.68
    },
    {
        "text": "week period and you can see that the",
        "start": 443.039,
        "duration": 3.44
    },
    {
        "text": "data become",
        "start": 445.12,
        "duration": 4.32
    },
    {
        "text": "more overwhelming in terms of vaccine",
        "start": 446.479,
        "duration": 4.321
    },
    {
        "text": "benefit",
        "start": 449.44,
        "duration": 4.4
    },
    {
        "text": "finally let's move to a high exposure",
        "start": 450.8,
        "duration": 4.0
    },
    {
        "text": "risk",
        "start": 453.84,
        "duration": 5.28
    },
    {
        "text": "and this one next slide please",
        "start": 454.8,
        "duration": 8.56
    },
    {
        "text": "is set typically at where we get to",
        "start": 459.12,
        "duration": 7.759
    },
    {
        "text": "in terms of a pandemic wave this is set",
        "start": 463.36,
        "duration": 4.88
    },
    {
        "text": "at the height of the",
        "start": 466.879,
        "duration": 3.6
    },
    {
        "text": "second pandemic wave that we went",
        "start": 468.24,
        "duration": 4.399
    },
    {
        "text": "through in the last few months",
        "start": 470.479,
        "duration": 6.241
    },
    {
        "text": "and i think is reflective of the kind of",
        "start": 472.639,
        "duration": 7.601
    },
    {
        "text": "scenario we want to avoid in",
        "start": 476.72,
        "duration": 6.0
    },
    {
        "text": "the forthcoming autumn and winter if we",
        "start": 480.24,
        "duration": 3.6
    },
    {
        "text": "possibly can",
        "start": 482.72,
        "duration": 3.919
    },
    {
        "text": "but here when there's a lot of covid19",
        "start": 483.84,
        "duration": 4.72
    },
    {
        "text": "circulating in the population",
        "start": 486.639,
        "duration": 5.361
    },
    {
        "text": "you can see that even in the 20 to 29",
        "start": 488.56,
        "duration": 7.359
    },
    {
        "text": "group the potential benefits in terms of",
        "start": 492.0,
        "duration": 5.199
    },
    {
        "text": "intensive care",
        "start": 495.919,
        "duration": 4.72
    },
    {
        "text": "admissions averted is very much higher",
        "start": 497.199,
        "duration": 6.321
    },
    {
        "text": "than the serious harms due to vaccine",
        "start": 500.639,
        "duration": 3.12
    },
    {
        "text": "and",
        "start": 503.52,
        "duration": 3.44
    },
    {
        "text": "and that's why the regulators",
        "start": 503.759,
        "duration": 6.56
    },
    {
        "text": "have concluded as they have about",
        "start": 506.96,
        "duration": 7.12
    },
    {
        "text": "risk benefit for the astrazeneca vaccine",
        "start": 510.319,
        "duration": 5.681
    },
    {
        "text": "so i hope that's placed it all into a",
        "start": 514.08,
        "duration": 3.92
    },
    {
        "text": "bit of context for everybody",
        "start": 516.0,
        "duration": 5.279
    },
    {
        "text": "so that i recognize it's been a detailed",
        "start": 518.0,
        "duration": 4.24
    },
    {
        "text": "scientific",
        "start": 521.279,
        "duration": 3.041
    },
    {
        "text": "discussion so far but hopefully those",
        "start": 522.24,
        "duration": 3.52
    },
    {
        "text": "figures bring it to life",
        "start": 524.32,
        "duration": 3.44
    },
    {
        "text": "and at this point i'm going to hand over",
        "start": 525.76,
        "duration": 3.759
    },
    {
        "text": "to um professor lim",
        "start": 527.76,
        "duration": 5.04
    },
    {
        "text": "to um give us the jcvi advice",
        "start": 529.519,
        "duration": 7.041
    },
    {
        "text": "thank you thank you jonathan",
        "start": 532.8,
        "duration": 6.32
    },
    {
        "text": "jcbi has been meeting over the last two",
        "start": 536.56,
        "duration": 3.12
    },
    {
        "text": "weeks",
        "start": 539.12,
        "duration": 3.04
    },
    {
        "text": "and we have carefully and independently",
        "start": 539.68,
        "duration": 3.44
    },
    {
        "text": "reviewed",
        "start": 542.16,
        "duration": 2.96
    },
    {
        "text": "the safety evidence and the benefit",
        "start": 543.12,
        "duration": 3.52
    },
    {
        "text": "evidence",
        "start": 545.12,
        "duration": 4.719
    },
    {
        "text": "given to us from mhra and public health",
        "start": 546.64,
        "duration": 4.0
    },
    {
        "text": "england",
        "start": 549.839,
        "duration": 3.361
    },
    {
        "text": "and that includes some of the kinds of",
        "start": 550.64,
        "duration": 4.4
    },
    {
        "text": "data that you've seen earlier on the",
        "start": 553.2,
        "duration": 3.84
    },
    {
        "text": "slide",
        "start": 555.04,
        "duration": 4.479
    },
    {
        "text": "we are well aware of the high level of",
        "start": 557.04,
        "duration": 4.16
    },
    {
        "text": "protection that covet 19",
        "start": 559.519,
        "duration": 4.961
    },
    {
        "text": "vaccines provide particularly against",
        "start": 561.2,
        "duration": 5.68
    },
    {
        "text": "serious disease that is hospitalization",
        "start": 564.48,
        "duration": 4.96
    },
    {
        "text": "i2 admission and from dying from corbett",
        "start": 566.88,
        "duration": 4.16
    },
    {
        "text": "19 disease",
        "start": 569.44,
        "duration": 4.079
    },
    {
        "text": "against that must be balanced the",
        "start": 571.04,
        "duration": 4.479
    },
    {
        "text": "uncertain occurrence of",
        "start": 573.519,
        "duration": 4.641
    },
    {
        "text": "an extremely rare adverse events that",
        "start": 575.519,
        "duration": 6.801
    },
    {
        "text": "may be associated with vaccination",
        "start": 578.16,
        "duration": 4.16
    },
    {
        "text": "acting really in the interest of safety",
        "start": 582.48,
        "duration": 4.799
    },
    {
        "text": "and for public benefit",
        "start": 585.279,
        "duration": 4.641
    },
    {
        "text": "jcvi feel that there are three points of",
        "start": 587.279,
        "duration": 5.12
    },
    {
        "text": "advice that we would like to put across",
        "start": 589.92,
        "duration": 5.52
    },
    {
        "text": "the first is that information given to",
        "start": 592.399,
        "duration": 4.0
    },
    {
        "text": "individuals",
        "start": 595.44,
        "duration": 3.6
    },
    {
        "text": "who are being offered vaccination and",
        "start": 596.399,
        "duration": 4.0
    },
    {
        "text": "information given to health",
        "start": 599.04,
        "duration": 2.56
    },
    {
        "text": "professionals",
        "start": 600.399,
        "duration": 3.201
    },
    {
        "text": "should be appropriately updated to",
        "start": 601.6,
        "duration": 3.52
    },
    {
        "text": "reflect the latest",
        "start": 603.6,
        "duration": 5.44
    },
    {
        "text": "considerations and deliberations by jcvi",
        "start": 605.12,
        "duration": 7.839
    },
    {
        "text": "and by mhra the second point",
        "start": 609.04,
        "duration": 6.08
    },
    {
        "text": "is that those who have received their",
        "start": 612.959,
        "duration": 4.801
    },
    {
        "text": "first dose of astrazeneca vaccine",
        "start": 615.12,
        "duration": 5.2
    },
    {
        "text": "should continue to be offered the second",
        "start": 617.76,
        "duration": 4.4
    },
    {
        "text": "dose of estrogenical vaccine",
        "start": 620.32,
        "duration": 5.28
    },
    {
        "text": "according to the set schedule",
        "start": 622.16,
        "duration": 5.919
    },
    {
        "text": "and the final bit of advice is that",
        "start": 625.6,
        "duration": 3.76
    },
    {
        "text": "adults who are aged",
        "start": 628.079,
        "duration": 5.361
    },
    {
        "text": "18 to 29 years old who do not have an",
        "start": 629.36,
        "duration": 5.919
    },
    {
        "text": "underlying health condition that puts",
        "start": 633.44,
        "duration": 3.2
    },
    {
        "text": "them at higher risk",
        "start": 635.279,
        "duration": 4.321
    },
    {
        "text": "from serious coveting disease should be",
        "start": 636.64,
        "duration": 3.6
    },
    {
        "text": "offered",
        "start": 639.6,
        "duration": 3.76
    },
    {
        "text": "an alternative coveting vaccine in",
        "start": 640.24,
        "duration": 5.839
    },
    {
        "text": "preference to the astrozenica vaccine",
        "start": 643.36,
        "duration": 5.12
    },
    {
        "text": "where such an alternative vaccine is",
        "start": 646.079,
        "duration": 4.161
    },
    {
        "text": "available",
        "start": 648.48,
        "duration": 4.64
    },
    {
        "text": "and perhaps it's useful to state what is",
        "start": 650.24,
        "duration": 4.08
    },
    {
        "text": "not advised",
        "start": 653.12,
        "duration": 4.32
    },
    {
        "text": "as well we are not advising a stop to",
        "start": 654.32,
        "duration": 6.24
    },
    {
        "text": "any vaccination for any individual in",
        "start": 657.44,
        "duration": 4.399
    },
    {
        "text": "any age group",
        "start": 660.56,
        "duration": 3.92
    },
    {
        "text": "we are advising a preference for one",
        "start": 661.839,
        "duration": 3.44
    },
    {
        "text": "vaccine",
        "start": 664.48,
        "duration": 3.68
    },
    {
        "text": "over another vaccine for a particular",
        "start": 665.279,
        "duration": 3.921
    },
    {
        "text": "age group",
        "start": 668.16,
        "duration": 4.32
    },
    {
        "text": "really out of the utmost caution",
        "start": 669.2,
        "duration": 5.68
    },
    {
        "text": "rather than because we have any serious",
        "start": 672.48,
        "duration": 6.08
    },
    {
        "text": "safety concerns",
        "start": 674.88,
        "duration": 3.68
    }
]